4-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester | 842170-27-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester
• 英文别名: methyl 5-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyrazine-2-carboxylate
• CAS: 842170-27-8
• 化学式: C₁₈H₁₇F₃N₄O₃
• 分子量: 394.353
• InChiKey: WYVAFAKXQLBOFY-UHFFFAOYSA-N

物化性质

• 沸点：
  561.3±50.0 °C(Predicted)
• 密度：
  1.371±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  75.6
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  4-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester 在 lithium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 19.0h， 以263 mg的产率得到5-(4-(2-(trifluoromethyl)benzoyl)piperazin-1-yl)pyrazine-2-carboxylic acid
  参考文献：
  名称：

  Discovery of Piperazin-1-ylpyridazine-Based Potent and Selective Stearoyl-CoA Desaturase-1 Inhibitors for the Treatment of Obesity and Metabolic Syndrome

  摘要：

  Stearoyl-CoA desaturase-1 (SCD1) catalyzes de novo synthesis of monounsaturated fatty acids from saturated fatty acids. Studies have demonstrated that rodents lacking a functional SCD1 gene have an improved metabolic profile, including reduced weight gain, lower triglycerides, and improved insulin response. In this study, we discovered a series of piperazinylpyridazine-based highly potent, selective, and orally bioavailable compounds. Particularly, compound 49 (XEN103) was highly active in vitro (mSCD1 IC50 = 14 nM and HepG2 IC50 = 12 nM) and efficacious in vivo (ED50 = 0.8 mg/kg). It also demonstrated striking reduction of weight gain in a rodent model. Our findings with small-molecule SCD1 inhibitors confirm the importance of this target in metabolic regulation, describe novel models for assessing SCD1 inhibitors for efficacy and tolerability and demonstrate an opportunity to develop a novel therapy for metabolic disease.

  DOI：

  10.1021/jm301661h
• 作为产物：
  描述：

  2-三氟甲基苯甲酰氯 在 四丁基碘化铵 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 90.0h， 生成 4-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester
  参考文献：
  名称：

  Discovery of Piperazin-1-ylpyridazine-Based Potent and Selective Stearoyl-CoA Desaturase-1 Inhibitors for the Treatment of Obesity and Metabolic Syndrome

  摘要：

  Stearoyl-CoA desaturase-1 (SCD1) catalyzes de novo synthesis of monounsaturated fatty acids from saturated fatty acids. Studies have demonstrated that rodents lacking a functional SCD1 gene have an improved metabolic profile, including reduced weight gain, lower triglycerides, and improved insulin response. In this study, we discovered a series of piperazinylpyridazine-based highly potent, selective, and orally bioavailable compounds. Particularly, compound 49 (XEN103) was highly active in vitro (mSCD1 IC50 = 14 nM and HepG2 IC50 = 12 nM) and efficacious in vivo (ED50 = 0.8 mg/kg). It also demonstrated striking reduction of weight gain in a rodent model. Our findings with small-molecule SCD1 inhibitors confirm the importance of this target in metabolic regulation, describe novel models for assessing SCD1 inhibitors for efficacy and tolerability and demonstrate an opportunity to develop a novel therapy for metabolic disease.

  DOI：

  10.1021/jm301661h

文献信息

• PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：Sviridov Serguei

  公开号：US20090030008A1

  公开（公告）日：2009-01-29

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where G, J, L, M, x, y, W, V, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 8a , R 9 , R 9a , R 10 , R 10a , R 11 and R 11a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明揭示了治疗哺乳动物（优选为人类）SCD介导的疾病或病状的方法，其中该方法包括向需要该方法的哺乳动物施用公式（I）的化合物：其中，G、J、L、M、x、y、W、V、R2、R3、R4、R5、R6、R7、R8、R8a、R9、R9a、R10、R10a、R11和R11a在此定义。本发明还揭示了包含公式（I）的化合物的制药组合物。
• Piperazine derivatives and their use as therapeutic agents
  申请人：Sviridov Serguei

  公开号：US20060252767A1

  公开（公告）日：2006-11-09

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where G, J, L, M, x, y, W, V, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 8a , R 9 , R 9a , R 10 , R 10a , R 11 and R 11a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明公开了治疗哺乳动物，尤其是人类SCD介导的疾病或病症的方法，其中所述方法包括向需要治疗的哺乳动物中给予式(I)的化合物，其中G、J、L、M、x、y、W、V、R2、R3、R4、R5、R6、R7、R8、R8a、R9、R9a、R10、R10a、R11和R11a在此被定义。本发明还公开了包含式(I)化合物的药物组合物。
• Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents
  申请人：Xenon Pharmaceuticals Inc.

  公开号：US08030488B2

  公开（公告）日：2011-10-04

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where G, J, L, M, x, y, W, V, R2, R3, R4, R5, R6, R7, R8, R8a, R9, R9a, R10, R10a, R11 and R11a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本文披露了一种治疗哺乳动物，尤其是人类SCD介导的疾病或病状的方法，其中该方法包括向需要治疗的哺乳动物投与下式(I)的化合物：其中G、J、L、M、x、y、W、V、R2、R3、R4、R5、R6、R7、R8、R8a、R9、R9a、R10、R10a、R11和R11a在此定义。本文还披露了包含上述化合物的制药组合物。
• US7456180B2
  申请人：——

  公开号：US7456180B2

  公开（公告）日：2008-11-25
• US8030488B2
  申请人：——

  公开号：US8030488B2

  公开（公告）日：2011-10-04